MedTrace Logo

Effects of SIMEOX on Flow and Volume in Healthy Subjects and Patients With COPD

NCT04150601 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-11-21

No results posted yet for this study

Summary

This study will investigate the effects on the SIMEOX technology on flow and volume generated in healthy subjects and patients with COPD

Conditions

  • Healthy
  • Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

SIMEOX

SIMEOX is a device generating a succession of gentle depression at the mouth.

DEVICE

PEP

A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.

OTHER

Spontaneous Exhalation

A slow vital capacity maneuver will be performed according to the guidelines, from total lung capacity to residual volume

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2021-11-16
Completion
2021-11-16

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04150601 on ClinicalTrials.gov